Cystic Fibrosis Committee meeting 8

Date: 01/03/2016

Royal College of Obstetricians and Gynaecologists, London.

Location:

Confirmed Minutes:

Committee members present:			
Martin Walshaw	(Present for notes 1 – 6)		
Mandy Bryon	(Present for notes 1 – 6)		
Alexander Darlington	(Present for notes 1 – 6)		
Iolo Doull	(Present for notes 1 – 6)		
Sarah Collins	(Present for notes 1 – 6)		
Alexander Darlington	(Present for notes 1 – 6)		
Zoe Elliot	(Present for notes 1 – 6)		
Helen McCabe	(Present for notes 1 – 6)		
Andrew Jones	(Present for notes 1 – 6)		
Keith Thompson	(Present for notes 1 – 6)		
Elaine Edwards	(Present for notes 1 – 6)		
David Lacy	(Present for notes 1 – 6)		
Nichola MacDuff	(Present for notes 1 – 6)		

In attendance:		
Vanessa Delgado Nunes	Senior Research Fellow and Guideline Lead	(Present for notes 1 – 6)
Annabel Flint	Project Manager	(Present for notes 1 – 6)
Shona Burman-Roy	Senior Research Fellow	(Present for notes 4 – 6)
Rami Cosulich	Research Assistant	(Present for notes 1 – 6)
Gemma Villanueva	Senior Research Fellow	(Present for notes 1 – 6)
Zosia Beckles	Information Scientist	(Present for notes 1 – 6)

Hugo Pedder	Statistician	(Present for notes 1 – 6)
Gemma Marceniuk	Health Economist	(Present for notes 1 – 6)
Katie Perryman-Ford	NICE Guideline Commissioning Manager	(Present for notes 1 – 6)
Stephen Holden	Co-opted member	(Present for notes 1 – 6)

Observers:	
None.	

Apologies:	
Stephen Murphy	Clinical Director
Janis Bloomer	Committee member
Sarah Popple	Committee member
Helen Parrott	Committee member
Stuart Elborn	Co-opted member
Sarah Catchpole	NICE Editor

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the eighth guideline committee meeting on Cystic Fibrosis. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received and these are noted above.

The Chair outlined the objectives of the meeting, which included: the drafting of the protocol for clinical manifestations of CF, the presentation of the evidence review and health economics for chronic antimicrobial treatment for P. aeruginosa, the evidence review for immunomodulatory agents and mucolytic treatment.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the diagnosis and management of Cystic Fibrosis.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Mandy Bryon	Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust	Invited speaker at a Cystic Fibrosis conference to present on the topic of mental health (how the impact of knowing a person has an incurable lifethreatening disease might affect their mental health) and Cystic Fibrosis. No fees received. 01/03/2016	Personal, non-financial, non-specific	Declare and participate (not covered as part of the guideline scope)
Sarah Collins	CF Specialist Dietician, Nutrition & Dietetic Department, Royal Brompton Hospital	Invited to be a member of the James Lind Alliance's Cystic Fibrosis Priority Setting Partnership (PSP) Steering Group, which is jointly funded by the UK CF Trust, the University of Nottingham and Nottingham Hospital NHS Trust Charity.	Personal non-financial, specific	Declare and participate
Elaine Edwards	Advanced Physiotherapist, Sheffield Children's NHS Foundation Trust	Attended the Association of Physiotherapists in Cystic Fibrosis (ACPCF) annual study days. Travel fees were reimbursed by Actavis UK Ltd 01/03/2016	Personal non- financial, specific	Declare and participate (expenses within NICE policy)
Nichola MacDuff	Adult Specialist Nurse, Advanced Clinical Nurse Specialist & Lead Nurse, Black	Teaching to GPs on inhaler devices and COPD guidelines sponsored by	Personal financial, non- specific	Declare and participate (COPD is not within the scope of the guideline)

	Country Adult CF Centre, Royal Wolverhampton NHS Trust	Astra Zeneca 01/03/2016		
Andrew Jones	Adult Physician, Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust	Invited to Chair the CF Trust Infection Control Group 01/03/2016	Specific non- financial personal	No further action necessary.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee whether any changes were required to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Hugo Pedder, Statistician and GM, Health Economist, who gave a presentation on the evidence reviewed for the topic of Immunomodulatory agents (NMA outcome results and non-NMA pairwise). The Chair then led the committee through the process of drafting recommendations and LETRs for this topic.

The Chair introduced Gemma Villanueva, Senior Research Fellow, and Gemma Merceniuk, Health Economist, who gave a presentation on the evidence review for the topic of mucolytic treatment. The Chair then led the committee through the process of drafting recommendations and LETRs for this topic.

Gemma Villanueva then gave a presentation on the evidence review for the topic of chronic antimicrobial treatment to suppress P.aruginosa (non-NMA outcome results).

The Committee thanked everyone for their presentations and contribution to the development of the guideline.

5. Questions and discussion

6. Any other business

There were no other items of business. MW thanked the Committee for attending and closed the meeting.

Date of next meeting: 26/04/16

Location of next meeting: Royal College of Obstetricians and Gynaecologists,

London.